Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic User Fee Negotiations May Be Falling Behind Schedule

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA and industry look to speed up the talks with GDUFA financial issues still to come.

You may also be interested in...



GDUFA II: FDA Prefers A ‘Manageable Number of High-Impact Changes’

Negotiations for generic drug user fee reauthorization open with FDA saying it doesn't want a large number of small tweaks that will increase program complexity.

Tentative Biosimilar Approvals Under Consideration By FDA

Concept could help sponsors who reach approvability but must wait several years before reference product exclusivity expires.

White House Reiterates Confidence In FDA Expertise, Independence With J&J Vaccine Pause

Not only did White House and other officials support the recommendation, but also made clear they had no advance notice of it.

Topics

UsernamePublicRestriction

Register

PS079229

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel